Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates

ABSTRACT:

Opinion statement

The treatment of advanced GIST is rapidly evolving with the development of novel molecular compounds such as avapritinib and ripretinib, but also promising results have been achieved with cabozantinib in a phase II trial. The availability of over five lines of treatment for patients with advanced GIST is likely to completely shift the current second-line and third-line treatment options, and will also potentially enable a personalised approach to treatment. Imatinib will most likely remain as the first-line treatment of choice for the vast majority of GIST patients. However, for GIST patients with tumours harbouring a D842V mutation in PDGFRA exon 18, avapritinib has shown efficacy and will become first-line therapy for this molecular subgroup. For second- and thi

SUBMITTER: Farag S 

PROVIDER: S-EPMC7253383 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature